Prostate cancer: ESMO Consensus Conference Guidelines 2012

被引：115

作者：

Horwich, A. ^{[1
]}

Hugosson, J. ^{[2
]}

de Reijke, T. ^{[3
]}

Wiegel, T. ^{[4
]}

Fizazi, K. ^{[5
]}

Kataja, V. ^{[6
]}

机构：

[1] Royal Marsden Hosp, Dept Radiotherapy, Inst Canc Res, Sutton SM2 5PT, Surrey, England

[2] Univ Gothenburg, Dept Urol, Sahlgrenska Acad, Gothenburg, Sweden

[3] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands

[4] Univ Ulm Klinikum, Klin Strahlentherapie & Radioonkol, Dept Radiooncol, Ulm, Germany

[5] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France

[6] Kuopio Univ Hosp, Ctr Canc, SF-70210 Kuopio, Finland

来源：

ANNALS OF ONCOLOGY | 2013年 / 24卷 / 05期

关键词：

consensus; ESMO; prostate cancer; ANDROGEN-DEPRIVATION THERAPY; PHASE-III TRIAL; INTENSITY-MODULATED RADIOTHERAPY; MITOXANTRONE PLUS PREDNISONE; CONFORMAL RADIATION-THERAPY; DIGITAL RECTAL EXAMINATION; DOSE-RATE BRACHYTHERAPY; LYMPH-NODE DISSECTION; I CLINICAL-TRIAL; QUALITY-OF-LIFE;

D O I：

10.1093/annonc/mds624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The first ESMO Consensus Conference on prostate cancer was held in Zurich, Switzerland, on 17-19 November 2011, with the participation of a multidisciplinary panel of leading professionals including experts in methodological aspects. Before the conference, the expert panel prepared clinically relevant questions about prostate cancer in four areas for discussion as follows: diagnosis and staging, management of early localized disease, management of advanced localized disease and systemic disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific question. The recommendations detailed here are based on an expert consensus after careful review of published data. All participants have approved this final update.

引用

页码：1141 / 1162

页数：22

共 202 条

[1] Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature [J].

Abrahamsson, Per-Anders .

EUROPEAN UROLOGY, 2010, 57 (01) :49-59

[2] European Association of Urology Position Statement on Screening for Prostate Cancer [J].

Abrahamsson, Per-Anders ;

Artibani, Walter ;

Chapple, Christopher R. ;

Wirth, Manfred .

EUROPEAN UROLOGY, 2009, 56 (02) :270-271

[3]

Adib RS, 1997, BRIT J UROL, V79, P235

[4] Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: Interim results of a randomized study in Japanese patients [J].

Akaza, H ;

Yamaguchi, A ;

Matsuda, T ;

Igawa, M ;

Kumon, H ;

Soeda, A ;

Arai, Y ;

Usami, M ;

Naito, S ;

Kanetake, H ;

Ohashi, Y .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (01) :20-28

[5] DOSE ESCALATION AND QUALITY OF LIFE IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH RADIOTHERAPY: LONG-TERM RESULTS OF THE DUTCH RANDOMIZED DOSE-ESCALATION TRIAL (CKTO 96-10 TRIAL) [J].

Al-Mamgani, Abrahim ;

van Putten, Wim L. J. ;

van der Wielen, Gerard J. ;

Levendag, Peter C. ;

Incrocci, Luca .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04) :1004-1012

[6] Cardiovascular Toxicity of Androgen Deprivation Therapy: A New Door Opens [J].

Alibhai, Shabbir M. H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) :3500-3502

[7] Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up [J].

Andriole, Gerald L. ;

Crawford, E. David ;

Grubb, Robert L., III ;

Buys, Saundra S. ;

Chia, David ;

Church, Timothy R. ;

Fouad, Mona N. ;

Isaacs, Claudine ;

Kvale, Paul A. ;

Reding, Douglas J. ;

Weissfeld, Joel L. ;

Yokochi, Lance A. ;

O'Brien, Barbara ;

Ragard, Lawrence R. ;

Clapp, Jonathan D. ;

Rathmell, Joshua M. ;

Riley, Thomas L. ;

Hsing, Ann W. ;

Izmirlian, Grant ;

Pinsky, Paul F. ;

Kramer, Barnett S. ;

Miller, Anthony B. ;

Gohagan, John K. ;

Prorok, Philip C. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (02) :125-132

[8] Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].

Andriole, Gerald L. ;

Grubb, Robert L., III ;

Buys, Saundra S. ;

Chia, David ;

Church, Timothy R. ;

Fouad, Mona N. ;

Gelmann, Edward P. ;

Kvale, Paul A. ;

Reding, Douglas J. ;

Weissfeld, Joel L. ;

Yokochi, Lance A. ;

Crawford, E. David ;

O'Brien, Barbara ;

Clapp, Jonathan D. ;

Rathmell, Joshua M. ;

Riley, Thomas L. ;

Hayes, Richard B. ;

Kramer, Barnett S. ;

Izmirlian, Grant ;

Miller, Anthony B. ;

Pinsky, Paul F. ;

Prorok, Philip C. ;

Gohagan, John K. ;

Berg, Christine D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319

[9] Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group [J].

Ankerst, Donna P. ;

Boeck, Andreas ;

Freedland, Stephen J. ;

Thompson, Ian M. ;

Cronin, Angel M. ;

Roobol, Monique J. ;

Hugosson, Jonas ;

Jones, J. Stephen ;

Kattan, Michael W. ;

Klein, Eric A. ;

Hamdy, Freddie ;

Neal, David ;

Donovan, Jenny ;

Parekh, Dipen J. ;

Klocker, Helmut ;

Horninger, Wolfgang ;

Benchikh, Amine ;

Salama, Gilles ;

Villers, Arnauld ;

Moreira, Daniel M. ;

Schroder, Fritz H. ;

Lilja, Hans ;

Vickers, Andrew J. .

WORLD JOURNAL OF UROLOGY, 2012, 30 (02) :181-187

[10]

[Anonymous], COCHRANE DATABASE SY

← 1 2 3 4 5 6 7 8 9 10 →